M.D., Chief Medical Officer, Cabaletta Bio
Biography
David J. Chang leads all clinical programs at Cabaletta Bio, which seeks to develop and launch the first, potentially curative, targeted cellular therapies for patients with autoimmune diseases. He is directing development of Cabaletta’s pipeline, including CABA-201, a fully human, 4-1BB containing CD19-CAR T cell product candidate, which has potential application across a broad range of autoimmune diseases such as SLE, rheumatoid arthritis, myositis, and systemic sclerosis. He is also leading programs with the highly specific Chimeric AutoAntibody Receptor T (CAART) approach, a precision therapy to eliminate disease-causing B cells, which is currently being evaluated in multiple clinical trials. Dr. Chang is a rheumatologist who received his medical education and training at NYU and Cornell and has >25 years of experience in immune-inflammation clinical development including as SVP of Inflammation, Autoimmunity and Neuroscience at AstraZeneca and in various senior positions at GSK. He also holds an adjunct professorship at the University of Pennsylvania.
Session Abstract – PMWC 2023 Silicon Valley
Track 1 - January 26 9.00 A.M.-4.30 P.M.
Track Chair: Sharon Benzeno, Adaptive Biotechnologies
- PMWC 2023 Luminary Award Ceremony
Honoree: Bruce Levine, University of Pennsylvania
- Advance and Optimize Cell Therapies in Oncology (PANEL)
Chair: Sharon Benzeno, Adaptive Biotechnologies
- Ira Mellman, Genenetch
- Mark Selby, Walking Fish Therapeutics
- Sneha Ramakrishna, Stanford
- Loïc VINCENT, Affini-T Therapeutics
- Nick Haining, Arsenal
- Warner Biddle, Kite - Pioneering Cell Therapies in the Treatment of Autoimmune Disorders (PANEL)
Chair: Carl June, UPenn
- Lenny Dragone, Sonoma
- James Chung, Kyverna
- David Chang, Cabaletta
- Cristina Musselli, Abata Therapeutics - Innovations in Cell Therapy Manufacturing (PANEL)
Chair: Bruce Levine, University of Pennsylvania
- Chris Holt, BMS
- Heidi Hagen, Sonoma Bio
- Rahul Singhvi, Resilience
- Snehal Patel, Sana Biotechnology - Patentability of Immunotherapies - Latest Developments
- Janet Xiao, Morrison & Foerster LLP
- Investing in Gene-Modified Cell Therapies
Chair: Karen Tkach Tuzman, BioCentury Inc.
- Robert Lin, UPMC
- Yvonne Yamanaka, venBio
- Abraham Bassan, Samsara Capital
- Brian Daniels, 5am Ventures
- Leveraging Data Sets to Inform Future Drug Discovery and Development (PANEL)
Chair: Jason Coloma, Maze Therapeutics
- Peter DiLaura, Sonoma Bio
- Nick Haining, Arsenal
- Kwame Okrah, Parker Institute
- Dan Kirouac, Notch Therapeutics
